Abstract: A solar cell support assembly includes: a plurality of support bases; a rotation shaft rotatably supported on the support bases; a frame connected to the rotation shaft to rotate with the rotation shaft and swung with respect to the rotation shaft in a pitch direction to change a pitch angle formed between the rotation shaft and the frame, the frame defining a first portion located above the rotation shaft and a second portion located below the rotation shaft; and a adjusting device disposed between the frame and the rotation shaft to adjust the pitch angle.

Abstract: A solar cell support assembly includes a plurality of support bases; swing bars; beams extended in a longitudinal direction and spaced from one another in a transverse direction, the beams connected to the plurality of the swing bars correspondingly, each of the beams rotatably supported on one of the plurality of support bases and adapted to mount solar panels, each of the beams comprising a hollow tube, and a wall thickness of each beam decreases gradually along a direction from a connecting position between the beam and the swing bar to two ends of the beam; a pushrod connected to the swing bars to drive the plurality of the swing bars to rotate the beams, respectively; and a driving device connected to the pushrod to drive the pushrod to move along the transverse direction.

Abstract: The invention relates to recombinant MVA which is capable of expressing structural HCV antigens, functional parts of said structural antigens or epitopes of said structural antigens. The invention further relates to a pharmaceutical composition, especially in the form of a vaccine and containing the recombinant MVA according to the invention, to eukaryotic cells that contain the inventive recombinant MVA and to various uses of the recombinant MVA, for example for producing recombinant structural proteins, for producing a pharmaceutical preparation that is suitable for the therapy and prophylaxis of HCV infections and diseases thereby caused. The invention further relates to methods for producing recombinant MVA and recombinant structural HCV polypeptides encoded by said recombinant MVA, and to DNA or RNA of said recombinant MVA.

Abstract: The invention relates to recombinant MVA which is capable of expressing structural HCV antigens, functional parts of said structural antigens or epitopes of said structural antigens. The invention further relates to a pharmaceutical composition, especially in the form of a vaccine and containing the recombinant MVA according to the invention, to eukaryotic cells that contain the inventive recombinant MVA and to various uses of the recombinant MVA, for example for producing recombinant structural proteins, for producing a pharmaceutical preparation that is suitable for the therapy and prophylaxis of HCV infections and diseases thereby caused. The invention further relates to methods for producing recombinant MVA and recombinant structural HCV polypeptides encoded by said recombinant MVA, and to DNA or RNA of said recombinant MVA.

Abstract: The invention relates to recombinant MVA which is capable of expressing structural HCV antigens, functional parts of said structural antigens or epitopes of said structural antigens. The invention further relates to a pharmaceutical composition, especially in the form of a vaccine and containing the recombinant MVA according to the invention, to eukaryotic cells that contain the inventive recombinant MVA and to various uses of the recombinant MVA, for example for producing recombinant structural proteins, for producing a pharmaceutical preparation that is suitable for the therapy and prophylaxis of HCV infections and diseases thereby caused. The invention further relates to methods for producing recombinant MVA and recombinant structural HCV polypeptides encoded by said recombinant MVA, and to DNA or RNA of said recombinant MVA.